Intepirdine

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial.  The Analyst...

Axovant Sciences Ltd (NASDAQ: AXON) suffered a setback in its phase 3 trial called MINDSET in which its exploratory drug called intepirdine failed to improve the quality of life in people suffering from Alzheimer's. The drug isn't intended to be a cure for the disease but the company expected the...

Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people with mild to moderate Alzheimer's disease (AD) after it was determined it had "virtually no chance of finding a positive clinical effect." In light...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...